Drug Discovery Outsourcing 2014 2024

Like this? Share it with your network

Share

Drug Discovery Outsourcing 2014 2024

  • 574 views
Uploaded on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website......

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1180/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024

More in: Business , Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
574
On Slideshare
574
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
14
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Drug Discovery Outsourcing World Market Forecast 2014-2024 & Future Prospects for Leading Companies ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  • 2. Contents 1. Executive Summary 1.1 Market Highlights 1.2 Overview of the Report Content 1.3 Research and Analysis Methods 1.4 Glossary of Terms Related to Drug Discovery Outsourcing 2. An introduction to Drug Discovery Outsourcing 2.1 What is Outsourcing? 2.1.1 Drug Discovery Outsourcing: Forming Global Networks 2.2 Why Outsource Drug Discovery? 2.2.1 The Move from Tactical to Strategic Outsourcing 2.2.2 The Advantages of Drug Discovery Outsourcing 2.2.3 Technological Advances Making In-House Drug Development Unsustainable 2.2.4 Emerging Markets Offering Reprieve from the Effects of Cost Pressures and Declining R&D Budgets 2.2.5 Strategic Partnerships: A Prequel to CRO Acquisition 2.2.6 Outsourcing to Improve Efficiency and Reduce Time-to-Market 2.3 Typically Outsourced Processes in Drug Discovery 2.4 A Paradigm Shift for Drug Development 2.4.1 Collaboration with Academia is Key for Pipeline Replenishment 2.5 Quality of Service is Integral for CRO Growth 2.6 Outsourcing: Reducing the Cost of Innovation 3. Global Drug Discovery Outsourcing Market 2014-2024 3.1 Drug Discovery Outsourcing: Global Market Overview 3.1.1 The Global Drug Discovery Outsourcing Market in 2012 and 2013 www.visiongain.com
  • 3. Contents 3.2 Global Drug Discovery Outsourcing: Market Forecast 2014-2024 3.2.1 Changing Market Shares by Sector 2014-2024 3.3 Global Chemistry Services Outsourcing Market 2014-2024 3.3.1 The Global Chemistry Services Outsourcing Market in 2012 and 2013 3.3.1.1 Libraries: Important for Cost Reduction and Time Efficiency 3.3.1.2 Custom Synthesis: A Major Driver for Long-Term Strategic Partnerships 3.3.1.3 Building Blocks: Promotes Efficiency of Drug Synthesis 3.3.2 Global Chemistry Services Outsourcing Forecast 2014-2024 3.4 Global Biology Services Outsourcing Market 2014-2024 3.4.1 The Global Biology Services Outsourcing Market in 2012 and 2013 3.4.1.1 Target Identification 3.4.1.2 Target Validation 3.4.2 Global Biology Services Outsourcing Forecast 2014-2024 3.5 Global Lead Optimization Market 2014-2024 3.5.1 The Global Lead Optimization Market in 2012 and 2013 3.5.1.1 ADMET Screening: To Prevent Late Stage Failure of Clinical Trials 3.5.2 Global Lead Optimisation Forecast 2014-2024 3.6 Global Lead Identification and Screening Outsourcing Market 2014-2024 3.6.1 The Global Lead Identification and Screening Outsourcing Market in 2012 and 2013 3.6.1.1 Methodologies of Lead Identification 3.6.2 Global Lead Identification and Screening Outsourcing Market: Forecast 2014-2024 4. Leading National Markets 2014-2024 4.1 Drug Discover Outsourcing – A Game of Supply versus Demand 4.1.1 The Global Distribution of Drug Discovery Outsourcing in 2012 and 2013 4.2 Leading National Markets: Forecast 2014-2024 4.2.1 Changing Market Shares by Region 2014-2024 4.3 Regional Drug Discovery Outsourcing Markets: Analysis and Forecasts 2014-2024 4.3.1 United States: Patent Expiries Boosting Pipeline Investment www.visiongain.com
  • 4. Contents 4.3.2 The EU5 Markets 4.3.2.1 EU5: Changing Market Shares by Country 2014-2024 4.3.2.2 Germany: Europe’s Largest Drug Discovery Outsourcing Market 4.3.2.3 UK: A Service-Oriented Market 4.3.2.4 France: Market Dominated by Large CROs 4.3.2.5 Italy: Heavy Investment from Multinational CROs will Drive Growth 4.3.2.6 Spain: An Immature Market with Potential 4.3.3 Japan: An Aging Population Putting a Strain on Pharma 4.3.4 The BRIC Nations: Rapid Growth will Fuel the Global Market 4.3.4.1 China: Rapid Market Expansion Fuelled by Acquisitions 4.3.4.2 India: R&D Infrastructure Needed for Market Boom 4.3.4.3 Brazil: The Largest Pharma Market in Latin America 4.3.4.4 Russia: A Highly Fragmented Market 4.3.5 South Korea: A Pharmaceutical Powerhouse of the Future 5. Leading Companies Offering Drug Discovery Services 5.1 Drug Discovery Outsourcing: An Expanding Marketplace 5.2 What Makes a Successful Contract Research Organisation? 5.2.1 A Business Model that Encourages Cost Reduction 5.2.2 A Workforce with Proven Expertise 5.2.3 Good Working Relationship: A Requisite for Outsourcing 5.2.4 Adequate Intellectual Property Protection 5.2.5 Huge Emphasis is placed on Communication and Timeliness 5.3 Leading Companies in the Drug Discovery Outsourcing Arena 5.4 Albany Molecular Research (AMRI) 5.4.1 SMARTSOURCING for Enhanced Decision-Making 5.4.2 AMRI’s Drug Discovery Services 5.4.3 AMRI’s Licensing Agreements and Drug Discovery Collaborations 5.4.4 AMRI Revenue Forecast 2014-2024 www.visiongain.com
  • 5. Contents 5.5 Aptuit 5.5.1 INDIGO: Aptuit’s Accelerated Drug Development Programme 5.5.2 Strategic Partnerships Strengthening Aptuit’s Outlook 5.6 Charles River Laboratories 5.6.1 Charles River: Strong Sales of Research Models Boosts Revenue 5.6.2 Charles Rivers: Corporate Restructuring to Maximise Efficiency 5.6.3 Charles River: Revenue Analysis and Forecast 2014-2024 5.7 Covance 5.7.1 Refocusing Early-Stage Efforts 5.7.2 Covance Strategic Partnerships 5.7.3 Covance: Revenue Analysis and Forecast 2014-2024 5.8 Cyprotex: An ADME-Tox Service Provider 5.8.1 Cyprotex: Revenue Analysis and Forecast 2014-2024 5.9 Domainex: Pipeline Products Showing Promise 5.10 Evotec: Discovery Alliances and Development Partnerships 5.10.1 Action Plan 2016 – Leadership in Drug Discovery Solutions 5.10.2 Evotec: Revenue Analysis and Forecast 2014-2024 5.11 Galapagos 5.11.1 Galapagos – Recent Activity 5.12 GenScript: A Biology-Focused Research Company 5.12.1 GenScript: Agreements and Partnerships 5.13 Pharmaceutical Product Development (PPD): A Leading CRO 5.13.1 PPD: Agreements, Strategic Partnerships and Private Merger 5.13.2 PPD’s Expansion in the Asian Markets 5.13.3 PPD and BioDuro: A Key Acquisition for Chinese Market Dominance 5.14 Quintiles: The World’s Largest Biopharmaceutical Services Company 5.14.1 Quintiles: Acquisition of Advion Bioanalytical Labs 5.14.2 Quintiles – New Developments 5.14.3 Quintiles: Revenue Analysis and Forecast 2014-2024 5.15 WIL Research Laboratories 5.16 WuXi AppTec: China’s Leading CRO www.visiongain.com
  • 6. Contents 5.16.1 WuXi AppTec: Revenue Analysis, 2008-2012 5.16.2 WuXi’s Strategic Partnerships and Recent Developments 5.16.3 WuXi AppTec: Revenue Forecast 2014-2024 6. Drug Discovery Outsourcing Market: Analysis and Trends 6.1 SWOT Analysis of the Drug Discovery Outsourcing Market 2014-2024 6.2 Strengths 6.2.1 Cost Reduction: A Central Driver for Outsourcing 6.2.2 Efficient Turnaround Times is Key for the Growth of Outsourcing 6.2.3 Acquisitions and Mergers allows for a more Comprehensive Service Provision 6.3 Weaknesses 6.3.1 The Negative Effects of Falling R&D Spending 6.3.2 Market Saturation and Poorly-Defined Service Offerings 6.4 Opportunities 6.4.1 The Available Scope for the Expansion of CROs 6.4.2 Targeted Therapies: Advances in Biologics and Orphan Drugs 6.4.3 Orphan Drug Development: An Opportunity for Higher Premiums 6.4.4 The Rise of Biologics and Biosimilars 6.4.5 The Multi-directional Expansion of CROs 6.4.6 The Rise of Virtual Pharma Companies 6.5 Threats 6.5.1 A Competitive Market Causing Smaller CROs to Miss Out 6.5.2 Private-Public Alliances May Become a Threat to Drug Discovery Outsourcing 6.5.3 Intellectual Property Leaks and the Challenges of Technology Transfer 6.5.4 Resource Sharing by Pharma Companies Could Restrain CRO Growth 6.6 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market 6.6.1 Power of Suppliers: Medium 6.6.2 Threat of Substitutes: Medium 6.6.3 Rivalry among Competitors: High www.visiongain.com
  • 7. Contents 6.6.4 Bargaining Power of Buyers: High 6.6.5 Threat of New Entrants: Medium 7. Expert Opinions 7.1 Interview with Dr Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium 7.1.1 Current State of the Drug Discovery Outsourcing Industry 7.1.2 Drug Discovery Collaborations between Pharma and Academia 7.1.3 Academic Research: A Restraint to CRO Growth? 7.1.4 The Changing Outsourcing Model: Implications for Pharma R&D 7.1.5 The Move towards Shared Risk Partnerships 7.1.6 Hot Therapeutic Areas in Drug Discovery 7.1.7 Views on the Future Prospects of the Market 7.2 Interview with Dr Mark Craighead, Director of Scientific Strategy, Redx Pharma 7.2.1 Changes in the Industry’s Pricing Model 7.2.2 Redx Pharma’s Services and Growth Plans 7.2.3 Is Outsourcing Earlier the Key to Solving Pharma’s R&D Problems? 7.2.4 Appealing Therapeutic Areas and the Role of the Asian Markets 8. Conclusion 8.1 Market Overview 8.2 A Move towards Biology Services 8.3 The Rise of the Asian Outsourcing Industry 8.4 Unmet Therapeutic needs will Stimulate Drug Discovery Drive 8.5 Alliances and Collaborations Will Continue to Dominate the Market www.visiongain.com
  • 8. Contents List of Tables Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2013 Table 2.2 Selected Drug Discovery Outsourcing Alliances 2012- 2013 Table 2.3 Selected Drug Discovery Outsourcing Alliances 2009- 2012 Table 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn) Table 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn), Market Shares (%) and Growth (%) by Sector, 2012 and 2013 Table 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2012-2017 Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2017-2024 Table 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017, 2017-2024, and 2012-2024 Table 3.6 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024 Table 3.7 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2024 Table 3.8 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 3.9 The Biology Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 3.10 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 3.11 Selected Drug Discovery Lead Optimisation Partnerships Table 3.12 Selected Methods for Sourcing Lead Compounds, 2013 Table 3.13 The Global Lead Identification and Screening Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) and Growth (%) by Region, 2012 and 2013 Table 4.2 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) www.visiongain.com
  • 9. Contents by Region, 2012-2017 Table 4.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2017-2024 Table 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017, 2017-2024, and 2012-2024 Table 4.5 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012, 2017, 2024 Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.7 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 20122024 Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Market Share (%) and CAGR (%), 2012-2024 Table 4.9 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2012-2017 Table 4.10 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2017-2024 Table 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 20122017, 2017-2024, and 2012-2024 Table 4.12 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012, 2017, 2024 Table 4.13 The German Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024 Table 4.15 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.16 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024 Table 4.17 The French Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024 www.visiongain.com
  • 10. Contents Table 4.18 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024 Table 4.19 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.20 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024 Table 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.22 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024 Table 4.23 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.24 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 4.25 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.26 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 4.27 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.28 The Indian Population: Demographic Forecast by Age Group (%), 2015, 2020, 2025 Table 4.29 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 4.30 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.31 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 4.32 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.33 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 www.visiongain.com
  • 11. Contents Table 4.34 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024 Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m, AGR %), 2008-2012 Table 5.2 AMRI: Services offered and Descriptions, 2013 Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 20122024 Table 5.5 Aptuit: Services Offered and their Descriptions, 2013 Table 5.6 Charles River Laboratories: Selected Services Provided, 2013 Table 5.7 Charles River: Historical Revenue ($m, AGR %), 2010-2012 Table 5.8 Charles River: Historical Revenue ($m) by Segment, 2009-2012 Table 5.9 Charles River: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 Table 5.10 Covance: Historical Revenue ($bn) by Business Segment, 2009-2012 Table 5.11 Covance: Early Development Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 Table 5.12 Selected Cyprotex Partnerships, 2013 Table 5.13 Cyprotex: Historical Revenue ($m) by Region, 2010-2012 Table 5.14 Cyprotex: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 Table 5.15 Domainex’s Collaborations and Partnerships, 2013 Table 5.16 Evotec: Historical Revenue ($m, AGR %), 2008-2012 Table 5.17 Evotec Action Plan 2016: Leadership in Drug Discovery Solutions Table 5.18 Evotec: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 Table 5.19 Galapagos Pipeline Projects and Development stages, 2013 Table 5.20 Galapagos: Historical operating Income ($m) by Business Sector, 2011 and 2012 Table 5.21 Genscript: Services Offered and Descriptions, 2013 Table 5.22 Quintiles: Historical Revenue ($bn, AGR %), 2008-2012 Table 5.23 Quintiles: Revenue Forecast ($bn, AGR %, CAGR%), 2012-2024 Table 5.24 WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2013 Table 5.25 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012 Table 5.26 WuXi AppTec: Laboratory Services Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 www.visiongain.com
  • 12. Contents Table 6.1 Drug Discovery Outsourcing: Market Drivers, 2014-2024 Table 6.2 Drug Discovery Outsourcing: Market Restraints, 2014-2024 Table 6.3 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2014-2024 Table 6.4 NIH Biomarker Definitions, 2013 Table 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn, CAGR%): 2012, 2017, 2020, 2024 Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024 Table 8.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024 www.visiongain.com
  • 13. Contents List of Figures Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013 Figure 2.2 Typical Stages of the Drug Development Cycle Figure 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn) Figure 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Sector, 2012 and 2013 Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2017 Figure 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2017-2024 Figure 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017 Figure 3.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2017-2024 Figure 3.7 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2024 Figure 3.8 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024 Figure 3.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2012 Figure 3.10 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2017 Figure 3.11 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2024 Figure 3.12 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 3.13 The Biology Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 3.14 An Overview of ADMET Screening in Drug Discovery Figure 3.15 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 3.16 Typical Steps in the Lead Screening Process Figure 3.17 The Global Lead Identification and Screening Market: Revenue Forecast ($bn), 20122024 Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Region, 2012 Figure 4.2 US, EU5, and Japan Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 20122024 Figure 4.3 China, India, South Korea, Brazil, and Russia Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017 Figure 4.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2017-2024 www.visiongain.com
  • 14. Contents Figure 4.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2024 Figure 4.7 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012 Figure 4.8 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017 Figure 4.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2024 Figure 4.10 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.11 Germany, UK, France, Italy, and Spain Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 20122024 Figure 4.13 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012 Figure 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.15 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.16 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.17 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.18 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024 Figure 4.19 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060 Figure 4.20 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.21 Chinese Demographics: Over 65 Population and Forecast (millions), 1950, 2010, 2050 Figure 4.22 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.23 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.24 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.25 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 20122024 Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2008-2012 Figure 5.2 Albany Molecular Research (AMRI): Revenue Forecast ($m), 2012-2024 Figure 5.3 Charles River: Historical Revenue ($m), 2010-2012 Figure 5.4 Charles River: Historical Revenue ($m) by Segment, 2012 Figure 5.5 Charles River: Revenue Forecast ($m), 2012-2024 Figure 5.6 Covance: Historic Revenue ($bn), 2009-2012 Figure 5.7 Covance: Revenue ($bn) by Segment, 2012 www.visiongain.com
  • 15. Contents Figure 5.8 Covance: Early Development Revenue Forecast ($m), 2012-2024 Figure 5.9 Cyprotex: Historical Revenue ($m), 2010-2012 Figure 5.10 Cyprotex: Revenue Shares (%) by Region, 2012 Figure 5.11 Cyprotex: Revenue Forecast ($m), 2012-2024 Figure 5.12 Evotec: Historical Revenue ($m), 2008-2012 Figure 5.13 Evotec: Revenue Forecast ($m), 2012-2024 Figure 5.14 Galapagos: Revenue Share (%) by Business Sector, 2012 Figure 5.15 Quintiles: Historical Revenue ($bn), 2008-2012 Figure 5.16 Quintiles: Revenue Forecast ($bn), 2012-2024 Figure 5.17 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012 Figure 5.18 WuXi AppTec: Laboratory Services Revenue Forecast ($m), 2012-2024 Figure 6.1 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market, 2013 Figure 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn): 2012, 2017, 2020, 2024 Figure 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024 Figure 8.3 Global Over-60 Population Forecast (%): 1950, 2009, 2050 Figure 8.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024 www.visiongain.com
  • 16. Contents Companies Mentioned in this Report Abbott Accugenix Advion Bioanalytical Albany Molecular Research Inc (AMRI) Andromeda Biotech (Teva) Apredica (Cyprotex) Aptuit Argenta (Galapagos) AstraZeneca Bayer Behrman Capital BioCity BioDuro (PPD) BioFocus (Galapagos) Biopontis Alliance Boehringer Ingelheim Bristol-Myers Squibb Caprion Proteomics Carlyle Group Catalent Pharma Solutions Cerebricon (Charles River) Charles River Laboratories ChemBridge ChemDiv Compound Focus (Evotec) Covance Crucell Cyprotex www.visiongain.com
  • 17. Contents Discovery Partners International Domainex Dow AgroSciences Dow Chemical Company Elan Eli Lilly Evotec Fidelity Growth Partners India (FGPI) Fidelta (Galapagos) Furiex Pharmaceuticals Galapagos Genentech GenScript GlaxoSmithKline (GSK) Glycoform Great Lakes Chemical Corporation Hangzhou Tigermed Consulting Hellman & Friedman Hypha Discovery i3 Research (inVentiv Health) ICON Inpharmatica InSphero InVentiv Health Johnson & Johnson (J&J) Janssen Pharmaceutical Group Kinaxo Knopp Biosciences ICON Immatics JOINN Laboratories www.visiongain.com
  • 18. Contents Laurus Labs Lonza MAB Discovery MedImmune Merck & Co. Microsoft Midwest BioResearch (WIL Research) Millipore Novartis Ono Pharmaceutical Oxford Asymmetry International Parexel Peking Union Lawke Biomedical Development Limited (PUL) Pfizer Myriad RBM Pharmaceutical Product Development (PPD) Pharmidex PharmaNet Development Group (inVentiv Health) Pharminox Piedmont Research Center (Charles River) PRA International ProSkelia ProStrakan Proteome Sciences Proteros Biostructures GmbH (Proteros) ProtonMedia Quintiles Ricerca Biosciences (WIL Research) Roche Samsung Sanofi www.visiongain.com
  • 19. Contents Sareum Holdings Plc Servier ShangPharma Corporation Shionogi Sirius Analytical Solvo Biotechnology Swiss Pharma Contract Sygnature Discovery SYNthesis Med Chem Taijitu Biologics Takeda Teva The Dow Chemical Company Tibotec TRAC Microbiology TransGenic UCB VitualScopics WIL Research Laboratories WuXi AppTec WuXi PharmaTech www.visiongain.com
  • 20. Contents Organisations Mentioned in this Report American Cancer Society Associação Brasileira de CROs (Abracro) Beijing Genomics Institute Bundesverband Medizinischer Auftragsinstitute (BVMA) CHDI Foundation Dundee University Food and Drug Administration (US FDA) Indiana Clinical and Translational Sciences Institute (CTSI) Johns Hopkins University Massachusetts General Hospital National Institute for Population and Social Security Research (IPSS) National Institutes of Health (NIH) Pharmaceutical Research and Manufacturers of America (PhRMA) Russian Corporation of Nanotechnologies Southwestern Medical Center The European Innovative Medicine Initiative (IMI) The European CRO Federation (EUCROF) The Institute of Cancer Research The Organization for Economic Cooperation and Development (OECD) University of Manchester University of North Carolina Wellcome Trust World Health Information Science Consultants (WHISCON) World Health Organization (WHO) World Trade Organization (WTO) www.visiongain.com
  • 21. Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013 Animal models Clinical trial data manageme t Pre-Clinical and Clinical Trials Registratio n and Marketing Clinical trial manageme nt Manufacturin g and packaging Regulator y affairs Lifecycle manageme nt Target identification Assay developme nt and ADMET Drug Discovery and Developme nt High throughput screening Drug manufacture Sales and marketing Lead Optimisation Source: Visiongain 2013 2.2 Why Outsource Drug Discovery? The global recession of 2008, triggered by the US housing bubble, has added to the global pharmaceutical industry’s existing challenges of declining pipeline products. The industry is currently experiencing one of the most challenging periods in its history, in terms of the level of capital available to be used. The cost of taking a drug to the market has risen rapidly over the past three decades. Development costs for a drug is now estimated to be anywhere between $800m and $1bn. The pharmaceutical industry has invested a large amount of money into R&D over the past few decades but the number of novel drug entities reaching the clinic has declined. All of www.visiongain.com Page 26
  • 22. Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 South Korean Market ($bn) Annual Growth (%) CAGR (% 2012-2017 & 2017-2024) CAGR (% 2012-2024) 0.2 0.2 0.2 0.3 0.3 0.4 0.5 0.6 0.6 0.7 0.8 0.9 1.0 18 20 22 22 21 18 15 15 14 13 14 12 20.6 14.4 16.9 Source: Visiongain 2013 Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024 1.2 1.0 0.9 1.0 Revenue ($bn) 0.8 0.7 0.8 0.6 0.6 0.4 0.2 0.2 0.2 0.3 0.3 0.4 0.5 0.6 0.0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Year Source: Visiongain 2013 Visiongain believes that the tax breaks afforded to local drug makers that invest in research and development, in particular, the subsidies afforded to those involved in joint drug-development www.visiongain.com Page 110
  • 23. Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage Disease Area/Target Antibacterials GLY-T 5-HT6 MCH-1 Biogenic Amines 5-HT3 Tubulin Inhibitor Lead Pre-clinical Optimisation Development Lead Discovery Phase I Clinical Phase II Clinical Infection Schizophrenia Cognition Obesity Central Nervous System Irritable Bowel Syndrome Oncology Source: AMRI 2013, Visiongain 2013 5.4.4 AMRI Revenue Forecast 2014-2024 Visiongain predicts sustained growth for AMRI’s future revenue. Increasing demand for chemistry services, especially from the US market will help AMRI grow contract revenue from its DDS business segment (Discovery, Drug development and Small scale manufacturing). This will reach $123.6m in 2017 (Figure 5.2). This represents a CAGR of 11.0% from 2012 to 2017 (Table 5.4). Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 2012-2024 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AMRI's DDS Revenue ($m) Annual Growth Rate (%) CAGR (% 2012-2017 & 2017-2024) CAGR (% 2012-2024) 73.5 83.7 94.6 106.0 114.5 123.6 131.0 138.9 148.6 156.1 162.3 168.8 173.9 14 13 12 8 8 11.0 6 6 7 5 4 4 3 5.0 7.4 Source: Visiongain 2013 www.visiongain.com Page 118